Lekha Pandit

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3482036/publications.pdf

Version: 2024-02-01

331259 1,889 68 21 h-index citations papers

g-index 68 68 68 2277 docs citations times ranked citing authors all docs

276539

41

#	Article	IF	CITATIONS
1	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 188-195.	0.9	13
2	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	1.4	16
3	Longitudinal Retinal Changes in <scp>MOGAD</scp> . Annals of Neurology, 2022, 92, 476-485.	2.8	20
4	<i>Clostridium bolteae</i> is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	26
5	Coexistence of autoantibodies and other autoimmune diseases with multiple sclerosis and related disorders – Experience from the Mangalore Demyelinating Disease Registry (MANDDIR). Annals of Indian Academy of Neurology, 2021, 24, 740.	0.2	7
6	Epidemiology and clinical features of demyelinating disorders in India. Neurology and Clinical Neuroscience, 2021, 9, 266-273.	0.2	2
7	Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines. Multiple Sclerosis Journal, 2021, 27, 1320-1322.	1.4	3
8	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. Multiple Sclerosis and Related Disorders, 2021, 53, 103080.	0.9	7
9	Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	47
10	Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay. Journal of Neuroimmunology, 2021, 360, 577706.	1.1	7
11	Evaluating the role of HLA DRB1 alleles and oligoclonal bands in influencing clinical course of multiple sclerosis – A study from the Mangalore demyelinating disease registry. Annals of Indian Academy of Neurology, 2021, 24, 356.	0.2	1
12	Role of Viral Infections in Multiple Sclerosis Pathogenesis among Indian Population. Neurology India, 2021, 69, 681.	0.2	4
13	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). BMJ Open, 2020, 10, e035397.	0.8	10
14	Treatment of MOG-lgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	0.9	110
15	Treatment of MOG antibody associated disorders: results of an international survey. Journal of Neurology, 2020, 267, 3565-3577.	1.8	64
16	Consensus statement on immune modulation in multiple sclerosis and related disorders during the covid-19 pandemic: Expert group on behalf of the indian academy of neurology. Annals of Indian Academy of Neurology, 2020, 23, 5.	0.2	15
17	Consensus Statement On Immune Modulation in Multiple Sclerosis and Related Disorders During the COVID-19 Pandemic: Expert Group on Behalf of the Indian Academy of Neurology. Annals of Indian Academy of Neurology, 2020, .	0.2	0
18	No evidence of disease activity (NEDA) in multiple sclerosis - Shifting the goal posts. Annals of Indian Academy of Neurology, 2019, 22, 261.	0.2	29

#	Article	IF	Citations
19	Reversible paraspinal muscle hyperintensity in anti-MOG antibody–associated transverse myelitis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e412.	3.1	9
20	MOG-lgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731878782.	0.5	26
21	Spontaneous remission lasting more than a decade in untreated AQP4 antibody-positive NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e351.	3.1	9
22	Anti myelin oligodendrocyte glycoprotein associated immunoglobulin G (AntiMOG-IgG)-associated neuromyelitis optica spectrum disorder with persistent disease activity and residual cognitive impairment. Annals of Indian Academy of Neurology, 2017, 20, 411.	0.2	8
23	Genetic variations in the Dravidian population of South West coast of India: Implications in designing case-control studies. Indian Journal of Medical Research, 2017, 145, 753.	0.4	2
24	Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731667563.	0.5	15
25	HLA associations in South Asian multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 19-24.	1.4	17
26	European multiple sclerosis risk variants in the south Asian population. Multiple Sclerosis Journal, 2016, 22, 1536-1540.	1.4	15
27	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 2016, 263, 140-149.	1.8	60
28	CD6 gene polymorphism rs17824933 is associated with multiple sclerosis in Indian population. Annals of Indian Academy of Neurology, 2016, 19, 491.	0.2	9
29	Serological markers associated with neuromyelitis optica spectrum disorders in South India. Annals of Indian Academy of Neurology, 2016, 19, 505.	0.2	24
30	Coexistence of autoimmune diseases and autoantibodies in patients with myasthenia gravis. Neurology India, 2016, 64, 7.	0.2	0
31	Environmental Factors Related to Multiple Sclerosis in Indian Population. PLoS ONE, 2015, 10, e0124064.	1.1	22
32	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	4.5	59
33	Demographic and clinical features of neuromyelitis optica: A review. Multiple Sclerosis Journal, 2015, 21, 845-853.	1.4	278
34	Human leukocyte antigen association with neuromyelitis optica in a south Indian population. Multiple Sclerosis Journal, 2015, 21, 1217-1218.	1.4	19
35	Neuromyelitis optica spectrum disorders: An update. Annals of Indian Academy of Neurology, 2015, 18, 11.	0.2	20
36	Approach to diagnosis and management of optic neuropathy. Neurology India, 2014, 62, 599.	0.2	9

#	Article	IF	CITATIONS
37	Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Multiple Sclerosis Journal, 2014, 20, 1651-1653.	1.4	104
38	Large unruptured proximal (A1) anterior cerebral artery aneurysm with aplasia of the contralateral A1. Neurology India, 2014, 62, 80.	0.2	0
39	Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report. Neurology India, 2014, 62, 646.	0.2	5
40	Association of Epstein–Barr virus infection with multiple sclerosis in India. Journal of the Neurological Sciences, 2013, 325, 86-89.	0.3	16
41	Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry. Annals of Indian Academy of Neurology, 2013, 16, 572.	0.2	21
42	Neoplastic Parkinsonism: An illustrative case report. Annals of Indian Academy of Neurology, 2013, 16, 437.	0.2	2
43	Association of vitamin D and multiple sclerosis in India. Multiple Sclerosis Journal, 2013, 19, 1592-1596.	1.4	29
44	Optic neuritis: Experience from a south Indian demyelinating disease registry. Neurology India, 2012, 60, 470.	0.2	29
45	Evaluation of the established non-MHC multiple sclerosis loci in an Indian population. Multiple Sclerosis Journal, 2011, 17, 139-143.	1.4	41
46	Insights into the Changing Perspectives of Multiple Sclerosis in India. Autoimmune Diseases, 2011, 2011, 1-5.	2.7	8
47	Treatment of multiple sclerosis. Annals of Indian Academy of Neurology, 2011, 14, 65.	0.2	10
48	Lymhomatosis cerebri â€" A rare cause of leukoencephalopathy. Journal of the Neurological Sciences, 2010, 293, 122-124.	0.3	17
49	Transverse myelitis spectrum disorders. Neurology India, 2009, 57, 126.	0.2	30
50	Autosomal recessive tubular aggregate myopathy in an Indian family. European Journal of Paediatric Neurology, 2009, 13, 373-375.	0.7	1
51	Tuberculous Spinal Meningitis. Infectious Diseases in Clinical Practice, 2009, 17, 281-282.	0.1	2
52	Differential diagnosis of white matter diseases in the tropics: An overview. Annals of Indian Academy of Neurology, 2009, 12, 12-21.	0.2	17
53	Invited commentary. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting. Neurology India, 2009, 57, 424-5.	0.2	1
54	Leprosy, Nerves, and Surgery. Infectious Diseases in Clinical Practice, 2008, 16, 345-348.	0.1	0

#	Article	IF	CITATIONS
55	A Review of Subdural Empyema and Its Management. Infectious Diseases in Clinical Practice, 2007, 15, 149-153.	0.1	31
56	Post-traumatic syringomyelia. Indian Journal of Orthopaedics, 2007, 41, 398.	0.5	13
57	Adult onset Leigh syndrome. Annals of Indian Academy of Neurology, 2007, 10, 55.	0.2	8
58	PRE-CHIASMATIC NERVE INJURY FOLLOWING FRONTAL CONTUSION. Electronic Journal of General Medicine, 2007, 4, 44-46.	0.3	0
59	NEUROGENIC PULMONARY OEDEMA. Electronic Journal of General Medicine, 2007, 4, .	0.3	2
60	Post-traumatic epilepsy: An overview. Clinical Neurology and Neurosurgery, 2006, 108, 433-439.	0.6	228
61	Neuromuscular disorders in critical illness. Clinical Neurology and Neurosurgery, 2006, 108, 621-627.	0.6	40
62	CRYPTOCOCCAL MENINGITIS AND PULMONARY CRYPTOCOCCOSIS IN A NON-HIV INFECTED PATIENT. Electronic Journal of General Medicine, 2006, 3, 80-82.	0.3	5
63	An illustrative case of hyperdense middle cerebral artery sign. Electronic Journal of General Medicine, 2006, 3, .	0.3	1
64	Diagnosis of partially treated culture-negative bacterial meningitis using 16S rRNA universal primers and restriction endonuclease digestion. Journal of Medical Microbiology, 2005, 54, 539-542.	0.7	41
65	Neurological manifestations of Hansen's disease and their management. Clinical Neurology and Neurosurgery, 2005, 107, 445-454.	0.6	68
66	Epilepsy care in six Indian cities: a multicenter study on management and service. Journal of the Neurological Sciences, 2001, 188, 73-77.	0.3	12
67	Economic Burden of Epilepsy in India. Epilepsia, 2001, 42, 1052-1060.	2.6	97
68	Acute thyrotoxic neuropathy—Basedow's paraplegia revisited. Journal of the Neurological Sciences, 1998, 155, 211-214.	0.3	28